The currently available human tumor xenograft models permit modeling of human cancers in vivo, but in immunocompromised hosts. Here we report a humanized mouse (hu-mouse) model made by transplantation of human fetal thymic tissue plus hematopoietic stem cells transduced with a leukemia-associated fusion gene MLL-AF9. In addition to normal human lymphohematopoietic reconstitution as seen in non-leukemic hu-mice, these hu-mice showed spontaneous development of B-cell acute lymphoblastic leukemia (B-ALL), which was transplantable to secondary recipients with an autologous human immune system. Using this model, we show that lymphopenia markedly improves the antitumor efficacy of recipient leukocyte infusion (RLI), a GVHD-free immunotherapy that induces antitumor responses in association with rejection of donor chimerism in mixed allogeneic chimeras. Our data demonstrate the potential of this leukemic hu-mouse model in modeling leukemia immunotherapy, and suggest that RLI may offer a safe treatment option for leukemia patients with severe lymphopenia.
Introduction
Mouse models are the most commonly used in vivo systems for cancer studies, in which immunotherapy can be studied in immunologically intact syngeneic hosts. However, because of the many differences between rodents and humans, much of the information on both pathogenesis and immunotherapies learned from the conventional mouse models cannot be applied to humans. For this reason, xenograft models have been increasingly used to study human tumors. In this model, human tumors can be grafted and grow in immunodeficient mice that lack immune system. To study interaction between the tumor and immune system, human peripheral blood mononuclear cells (PBMCs) or T cells were transferred into the immunodeficient mice bearing human tumors. However, the immune responses are not physiological for two reasons. First, xenoantigen-reactive T cells in the injected human cells cause graft-vs.-host responses. Second, because human antigen-presenting cells (APCs) are lacking, such system can neither maintain peripheral T cell pool nor initiate human leukocyte antigen (HLA)-restricted immune responses.
Functional human hematopoietic and lymphoid systems can be established in mice by transplantation of human fetal thymic tissue (FTHY) and CD34 + fetal liver cells (FLCs) to sublethally-irradiated immunodeficient mice (Lan et al., 2006; Lan et al., 2004; Melkus et al., 2006) . These hu-mice have proved to be an excellent model for assessing human innate and adaptive immune responses in vivo under normal or pathological conditions such as human immune responses to allo-and xeno-antigens and viral infection (Hu and Yang, 2012) . Here, we seek to develop hu-mice with human lymphohematopoietic systems and autologous leukemia that permit exploration of human cancer immunotherapy.
Materials and Methods

Animals and Human Tissues and Cells
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NOD/SCID/γc −/− or NSG) mice were purchased from the Jackson Laboratory (Bar Harbor, ME), and were housed in a specific pathogen-free micro-isolator environment and used in experiments at 6 to 10 weeks of age. Human fetal thymus and liver tissues of gestational age of 17 to 20 weeks were obtained from Advanced Bioscience Resource (Alameda, CA 
Retroviral Transduction of CD34 + FLCs
Pseudo-typed retroviruses were produced by transfection using Lipofectamine 2000 (Invitrogen, San Diego, CA) of 293FT cells with a 3-plasmid system consisting of the MLL fusion vector (MSCV-MLL-AF9-human pgk-EGFP; kindly provided by Dr. John Dick) (Barabe et al., 2007) and two packaging vectors (VSV-G and PsiEnv). Viral particles were collected 48 or 72 h post-transfection and concentrated by ultracentrifugation at 50,000 g for 2 h, and were titered and stored at − 80°C until use. For transduction, human CD34 + FLCs were stimulated overnight in medium containing 50 ng/mL rhSCF (R&D, Minneapolis, MN), 50 ng/mL Flt-3L (eBioscience, San Diego, CA), 25 ng/mL TPO (R&D, Minneapolis, MN), 10 ng/mL IL-3 (R&D, Minneapolis, MN), in 24-well plates precoated with Retronectin (Takara Bio Inc.), followed by incubation with retroviruses for 12 h. Cells were washed twice and injected into sublethally irradiated NSG mice to generate leukemic hu-mice (see Hu-mouse preparation below) . A small aliquot of the transduced cells was cultured for 3 additional days to determine the transduction efficiency by measuring the ratio of GFP + cells using FACS (ranged between 10 and 30% in the experiments presented).
Humanized Mouse Preparation
NSG mice were conditioned with sublethal (2 Gy) total body irradiation (TBI), and transplanted intravenously (i.v.) or intrafemorally (i.f.) with human CD34 + FLCs (0.5-2 × 10 5 /mouse) alone or along with thymic tissue fragment measuring about 1 mm 3 (under mouse kidney capsule) from the same fetal donor, as previously described (Lan et al., 2006; Tonomura et al., 2008) . Levels of human hematopoietic cells in hu-mice were determined by flow cytometric analysis using various combinations of the following mAbs: antihuman CD45, CD3, CD4, CD8, CD45RA, CD45RO, CD19, CD20, CD10, IgM, IgD, CD44, CD33, CD14, CD15, CD11b, CD11c, CD56, CD34, HLA-DR, HLA-A/B/C; anti-mouse CD45 and Ter119; and isotype control mAbs (all antibodies were purchased from BD PharMingen, San Diego, CA). Analysis was performed on a LSR II (Becton Dickinson, Mountain View, CA), and dead cells were excluded from the analysis by gating out lower forward scatter and high propidium iodide or DAPI-retaining cells. For making hu-mice with autologous leukemia, NSG mice were injected with CD34 + FLCs that were transduced with retroviral vectors containing MLL-AF9, and leukemia development was assessed by FACS and histology.
Cytospin and Histology Analysis
Bone marrow or spleen cells were prepared from leukemic hu-mice and GFP + human leukemia cells were purified by cell sorting, suspended in PBS, and centrifuged (130 g for 5 min) onto glass slides using a Cytospin centrifuge (Shandon). The slides were stained with the DipQuick Stain Kit (modified Wright Giemsa staining) from Jorgensen Laboratories. Tissues from leukemic hu-mice were fixed in 10% buffered formalin and embedded in paraffin for hematoxylin and eosin (H&E) staining. Stained slides were examined under a Zeiss microscope and photographed using a Nikon Coolpix 5000 digital color camera.
Hydrodynamic Gene Delivery
Human cytokine genes (IL-15/Flt-3L/GM-CSF/IL-3) were cloned separately into pcDNA3.1(+) vector (Invitrogen) (Chen et al., 2012; Chen et al., 2009) . Plasmid DNA was purified by Maxi-prep Kit (Qiagen), and injected i.v. into hu-mice 12 days prior to RLI (5-50 μg of each plasmid in a total of 1.8-mL saline within 7 s using a 27-gauge needle) (Suda et al., 2007) .
In Vivo Human T Cell Depletion
Hu-mice were treated with 6 injections (i.v.) of anti-huCD3-immunotoxin (a gift from Dr. David Neville (Woo et al., 2010) ) with the dose of 5 μg/Kg BID for 3 days (6, 5 and 4 days before RLI). Right before each day injections, blood samples were collected for FACS analysis. Some hu-mice were sacrificed to confirm the depletion of human T cells in periphery and organs by FACS 3 days after the treatment was completed.
Recipient Lymphocyte Infusions
Spleen cells were prepared from RLI-cell source hu-mice and administered i.v. at a dose of 2-3 × 10 7 cells per mouse into hu-mouse chimeras 11-12 weeks after human CD34 + cell transplantation. In some experiments, human CD25 + cells were depleted from RLI inoculum by MACS using anti-human CD25 microbeads (Miltenyi Biotech, Aubum, CA).
Statistical Analysis
The level of significant differences in group means was determined by the Student's t-test for parametric data sets. The overall difference between groups was determined by two-way ANOVA with repeated measures. All analysis was performed using Prism 5 (GraphPad Software). A P value of ≤ 0.05 was considered significant in all analyses.
Results
Construction of Humanized Mice With Human Immune System and Autologous Leukemia
We transplanted sublethally-irradiated NSG mice with human FTHY and CD34 + FLCs that were transduced with retrovirus containing a mixed-lineage leukemia (MLL) fusion gene MLL-AF9 (Barabe et al., 2007) (Fig. 1a) . FACS analysis revealed a gradual increase in the levels of human PBMCs, including T and B cells and myeloid cells (or APCs), with a similar kinetics as that seen in hu-mice receiving untransduced CD34 + FLCs (Lan et al., 2006) , until 15 weeks when overt leukemia appeared (Fig. 1b) . The hu-mice became moribund between 19 and 24 weeks after transplantation (Fig. 1c) ; autopsy revealed splenomegaly, enlarged lymph nodes, hepatomegaly, and enlarged FTHY grafts in all of these mice ( Fig. 1d and 
Leukemia with a similar B-ALL phenotype also developed in mice receiving MLL-AF9-transduced CD34 + FLCs without FTHY (Table 1) . Therefore, this leukemic hu-mouse model not only establishes human lymphohematopoietic system, but also Macroscopic evidence of tumor in lymph node and spleen (left) and sizes (mean ± SDs) of spleens from leukemic and non-leukemic hu-mice. *** P b 0.001. develops B-ALL driven by MLL-AF9 transduction, thus providing a model to study human tumor immunology to autologous leukemia. Bone marrow or spleen cells, when adoptively transferred into sublethally-irradiated NSG mice, induced lethal leukemia in a cell number-dependent manner (Fig. S1a-b) . The leukemia cells were also transplantable in hu-mice with an established autologous human immune system (i.e., transplanted with FTHY and CD34 + FLCs from the same fetus from which CD34 + FLCs were used to make the leukemic hu-mice), in which all recipient hu-mice showed detectable GFP + leukemia cells in blood within 2 weeks and died by 49 days following injection of 1 × 10 5 leukemia cells (Fig. 2d ). In contrast, the leukemia cells were rejected in hu-mice with an allogeneic immune system, i.e., hu-mice made of FTHY and CD34 + FLCs from a different fetus (Fig. S1c) . Together, our data demonstrate that these leukemia cells are transplantable in immune compromised recipients or recipients with autologous immune system, thereby offering another means of creating hu-mice with a functional human lymphohematopoietic system and autologous leukemia. These data also demonstrate that human alloresponses can reject leukemia in hu-mice.
Lymphopenia Enhances Anti-leukemia Responses of Recipient Leukocyte Infusion in Mixed Chimeric Hu-mice
Previous studies have shown that administration of recipient leukocyte infusion (RLI) to mixed allogeneic chimeras results in loss of donor hematopoietic chimerism and anti-host leukemia responses (Rubio et al., 2003) . Although the anti-leukemia response of RLI is significantly weaker than that of alloreactive donor leukocyte infusion (DLI) (Saito et al., 2006) , RLI does not induce GVHD, presenting a safe approach for use in combination with other strategies of augmenting immune responses. Lymphopenia occurs frequently in patients with hematological malignancies who receive allo-HCT (Heining et al., 2007; Small et al., 1999) and promotes both antitumor responses (Dudley et al., 2002; Quezada et al., 2010) and GVHD Miller et al., 2007) . Here we seek to employ lymphopenia to enhance antitumor responses of RLI in a human immune system using the leukemic hu-mouse model described above. Antitumor responses of RLI in murine mixed chimeras (MCs) depend on host-vs.-graft reaction (HVGR), which in turn provokes immune responses to tumor-associated antigens expressed by recipient leukemia cells (Rubio et al., 2005; Rubio et al., 2006 (Hu and Yang, 2012) , human T cells from the RLI-cell source hu-mice should show tolerance to only the 'recipient', but not the 'donor' alloantigens and could therefore mediate anti-'donor' alloresponses after injection into the MCs. Spleen cells were prepared from the RLI-cell source hu-mice 11 weeks after transplantation, when significant human T cell reconstitution was established (Fig. S2) , and injected i.v. (i.e., RLI; 2 × 10 7 /mouse) into hu-mouse MCs.
FACS analysis revealed successful reconstitution with human hematopoietic cells and the establishment of mixed human chimerism in humouse MCs (Figs. 3b and S3 ). Human T cells were barely detectable in MCs that did not receive FTHY (i.e., Lymphopenic group; Figs. 3c and S3). Comparing to that in the non-lymphopenic MCs, RLI T cells exhibited significantly more robust activation in the lymphopenic MCs, shown by a marked increase in the proportion of HLA-A2 − 'recipient' CD3 + T cells (Fig. 3c) , and of 'recipient' CD4 + and CD8 + T cells expressing a CD45RA − CD45RO + effector/memory phenotype (Fig. 3d) . After RLI, lymphopenic, but not non-lymphopenic, MCs showed a rapid decline in the levels of 'donor' (HLA-A2 + ) hematopoietic (CD45 + ) cells (Fig.  3b) . To determine whether the decrease of 'donor' human chimerism resulted from dilution due to the expansion of HLA-A2
− RLI T cells, we analyzed donor chimerism in the human B cell compartment. The ratios of 'donor' (HLA-A2 + ) CD19 + B cells to 'recipient' in the lymphopenic and non-lymphopenic MCs were comparable prior to RLI, but became significantly lower in the former than in the latter group after RLI (Fig.  3e) . We conclude that lymphopenia significantly enhanced RLI-mediated HVGR in MCs. We next assessed the potential of lymphopenia to promote RLI-mediated anti-leukemia responses in MCs. Lymphopenia commonly seen in leukemia patients who need HCT is mainly induced by conditioning treatment and/or chemotherapy (Heining et al., 2007) , and a lack of thymic reserve (Small et al., 1999) . Thus, to simulate lymphopenia in leukemia patients, we depleted T cells by anti-huCD3-immunotoxin in the hu-mouse MCs that had received a mixture of 'recipient' (HLA-A2 + )
and allogeneic 'donor' (HLA-A2 − ) CD34 + FLCs with implantation of 'recipient' FTHY (Fig. 4a) . We then enhanced RLI effects by manipulating APCs and regulatory T cells (Tregs) in the hu-mouse MCs. Although data presented in Fig. 3 show that RLI mediated significantly stronger HVGR in lymphopenic than in non-lymphopenic hu-mouse MCs, the response was generally low in these mice, so as to be undetectable in the non-lymphopenic MCs. Because RLI-mediated HVGR in mouse models is largely dependent on donor APCs , the weak alloreactivity of RLI in the hu-mice may be caused by low numbers of APCs in the MCs. Thus, to boost human myeloid reconstitution, we treated hu-mouse MCs with human cytokines 12 days prior to RLI (Fig. 4a) . The production of human cytokines (IL-15, Flt-3L, GM-CSF and IL-3) in hu-mouse MCs was achieved by hydrodynamic injection of the cytokine-containing plasmids as previously described (Fig. 4a) (Chen et al., 2009 (Fig. S4) . Another factor that may inhibit RLI-mediated alloreactivity is the presence of relatively high levels of Tregs in the RLI inoculum (Fig. S5) . Therefore, we also depleted CD25 + cells from RLI inoculum to enhance the RLI effect in the following experiments (see below and Fig. S7a ). T cell lymphopenia was induced in hu-mouse MCs by i.v. injection of anti-huCD3-immunotoxin (Woo et al., 2010) (5 μg/Kg BID for 3 consecutive days) starting 6 days prior to RLI (Fig. 4a) . T-cell depletion in MCs was confirmed by FACS analysis (Fig. S6) . RLI-cell source hu-mice were made by transplantation of 'recipient' FTHY and CD34 + FLCs as described above. After depletion of CD25 + human
Tregs (Foxp3 + cells were mainly in the CD4 + CD25 + population, Fig. S7a ), the RLI source cells contained approximately 34% human CD3 + T cells (with a CD4/CD8 ratio of about 3:1), in which most of the cells expressed a naïve phenotype (Fig. S7b) . These RLI source cells were intravenously injected into hu-mouse MCs 4 days after the last injection of anti-huCD3-immunotoxin (12 weeks after FTHY/CD34 + FLC transplantation). Autologous leukemia cells were given to the hu-mouse MCs 1 day prior to RLI in order to assess the antitumor responses. Because anti-huCD3-immunotoxin has a very short in vivo half-life (approximately 45 min) (Woo et al., 2010) , the conditioning treatment should not affect the function of RLI T cells given 4 days after the treatment. FACS analysis of blood cells revealed that RLI was significantly more effective in eliminating donor hematopoietic cells in the lymphopenic than in control MCs. As shown in Fig. 4b, vs. 79% 1 week prior to RLI, 75% vs. 45% 3 weeks post-RLI, and 52% vs. 21% 6 weeks post-RLI, respectively. Similar changes were seen in the CD19 + B cell population (Fig. 4b, right) . The percentages of HLA-A2 + 'recipient' T cells (including CD4 + and CD8 + subsets) in total human GFP − PBMCs increased rapidly and extensively in MCs with lymphopenia than in those without (Fig. 4c) . Furthermore, more human HLA-A2 + 'recipient' T cells (including both CD4 + and CD8 + subsets) expressed a CD45RA − CD45RO + activated/memory phenotype in MC recipients with lymphopenia than in those without (Fig. 4d) . We conclude that lymphopenia significantly enhances RLI induced HVGR. The stronger HVGR in the lymphopenic MCs was associated with an increased antitumor response. FACS analysis of blood cells showed that the percentages of leukemia cells at weeks 3 and 6 post-RLI were 1.4 and 5.5 fold higher, respectively, in control MCs than in lymphopenic MCs (Fig. 4e, left) . All mice were sacrificed at week 7 to measure leukemia cell counts. As shown in Fig. 4e (right) , the control MCs had significantly more leukemia cells in the bone marrow and spleen than lymphopenic MCs. These data indicate that lymphopenia can significantly enhance RLI-mediated anti-leukemia responses in MCs.
Discussion
We report a unique hu-mouse model that permits testing human leukemia immunotherapy in recipients with functional human lymphohematopoietic systems. In addition to hu-mice having both normal human lymphohematopoietic systems and autologous leukemia, this model also enables the production of non-leukemic humice with functional human lymphohematopoietic systems that are autologous or allogeneic to the leukemia. Thus, this model has potential for assessing adoptive immunotherapies using either autologous or allogeneic effectors. This hu-mouse model offers, to our knowledge, the only model available to date that permits in vivo analysis of antitumor immune responses to autologous human cancers and evaluation of anti-leukemia therapies in the presence of a human immune system. As an example, we recently confirmed the superiority of this model in testing and validating adoptive immunotherapy using autologous human T cells that are modified to express anti-CD19 chimeric antigen receptors (CARs; data not shown).
MLL-AF9 has been found to be associated with both ALL and acute myeloid leukemia (AML), but MLL-AF9 leukemia manifests more often as ALL in infants, whereas almost always as AML in adults (Meyer et al., 2013) . Consistently, a previous mouse study suggests that the age of HSCs is involved in the lineage determination of MLL-AF9 leukemia, as MLL-AF9 leukemia derived from adult mouse marrow HSCs was myeloid in character with myeloperoxidase (MPO) positivity and negative for CD45R/B220, whereas MLL-AF9 leukemia derived from fetal mouse liver HSCs was positive for CD45R/B220 and negative for MPO (Chen et al., 2011) . Thus, the use of fetal liver CD34 + cells might be a possible reason for the observed preference for B-ALL development in our model. However, our recent study showed that the lineage determination of MLL-AF9-driven leukemia in mice is also largely affected by the cytokine environment, as provision of human hematopoietic cytokines markedly increased the chance of AML development from MLL-AF9-transduced human CD34 + FLCs (unpublished data).
During allogeneic hematopoietic cell transplantation (allo-HCT), donor T cells mediate beneficial graft-vs.-tumor (GVT) effects. However, donor T cells also attack host normal tissues, resulting in graft-vs.-host disease (GVHD). Intriguingly, antitumor responses and sustained remissions of advanced chemo-refractory hematologic malignancies were also seen in patients who rejected donor grafts after nonmyeloablative allo-HCT (Dey et al., 2005) . Mouse studies further demonstrated that administration of RLI to mixed allogeneic chimeras results in loss of donor hematopoietic chimerism and anti-host leukemia responses (Rubio et al., 2003) . Although RLI mediates significantly weaker antileukemia response than DLI (Saito et al., 2006) , RLI does not induce GVHD, presenting a safe approach for patients with a high risk of GVHD. Our data show that the antitumor response of RLI can be significantly potentiated in lymphopenic recipients, indicating that RLI may be a potential treatment option for leukemia patients with lymphopenia, an independent risk factor for GVHD following allo-HCT .
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